archive-com.com » COM » A » AGENDIA.COM

Total: 235

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Managed Care | Agendia
    Provides Clinically Useful Solutions for Early Stage Breast Cancer Patients Agendia is a leading molecular diagnostics company that develops and markets FFPE based genomic diagnostic products which help support physicians with their complex treatment decisions Agendia s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome Agendia s tests can help physicians assess a patient s individual risk for metastasis which patients may benefit from chemo hormonal or combination therapy and which patients may not require these treatments and can instead be treated with other less arduous and less costly methods Clinical Solutions Agendia offers a unique solution for physicians and their cancer patients The signatures for early stage breast and colon cancer are based on the analysis of the entire human genome and provide unprecedented biological insight to address complex treatment decisions Click image to enlarge Agendia s product portfolio includes MammaPrint 70 Gene Breast Cancer Recurrence Assay BluePrint 80 Gene Molecular Subtyping Assay TargetPrint an ER PR HER2 Expression Assay ColoPrint 18 Gene Colon Cancer Recurrence Assay We d Love To Hear From You Name Email Questions Comments Concerns Questions Comments Concerns Comments This field is for validation purposes and should

    Original URL path: http://www.agendia.com/healthcare-professionals/managed-care/ (2016-05-01)
    Open archived version from archive


  • Educational Presentations | Agendia
    with IDC 1 7cm mass grade III ER 60 PR 30 HER2 neg Recurrence Score of 10 The Reclassified Basal type Patient Massimo Cristofanilli MD Is her tumor really Luminal type 54 y o woman diagnosed with IDC large palpable mass 4 5x 3 5 cm ER 5 PR 4 HER2 neg The Low Risk Lymph Node Positive Patient Fatima Cardoso MD Will she benefit from chemotherapy 50 y o diagnosed with IDC grade II 2 1cm mass ER 85 PR 80 HER2 neg Ki67 5 LN NBRST Study Results using BluePrint Molecular Subtyping Dr Pat Whitworth MD discusses the results of the NBRST study showing how BluePrint Molecular Subtyping more accurately identified patients who may benefit from neoadjuvant chemotherapy Share This Video http www youtube com watch v XkDyYvkw LQ NBRST Study Results using BluePrint Molecular Subtyping Dr Pat Whitworth MD discusses the results of the NBRST study showing how BluePrint Molecular Subtyping more accurately identified patients who may benefit from neoadjuvant chemotherapy Share This Video http www youtube com watch v XkDyYvkw LQ Benefits of MammaPrint and BluePrint on treatment decisions for breast cancer Dr Massimo Cristofanilli MD discusses the benefits of using the MammaPrint 70 Gene assay and the BluePrint 80 Gene assay in the treatment process for breast cancer Share This Video http www youtube com watch v dncAO2 5mFA Benefits of MammaPrint and BluePrint on treatment decisions for breast cancer Dr Massimo Cristofanilli MD discusses the benefits of using the MammaPrint 70 Gene assay and the BluePrint 80 Gene assay in the treatment process for breast cancer Share This Video http www youtube com watch v dncAO2 5mFA UPMC study results at ASCO 2014 Dr Adam Brufsky MD PhD discusses a study comparing MammaPrint to the 21 gene assay and how BluePrint molecular subtyping compares

    Original URL path: http://www.agendia.com/healthcare-professionals/educational-presentations/ (2016-05-01)
    Open archived version from archive

  • Breast Cancer Patients | Agendia
    breast cancer recurrence score Breast cancer patient Cari G explains how MammaPrint s definitive results helped her and her physician choose the best course of treatment when she was initially given an ambiguous Intermediate result from the 21 gene assay Share This Video http www youtube com watch v Hnj5U7YLnDg Dealing with an intermediate breast cancer recurrence score Breast cancer patient Cari G explains how MammaPrint s definitive results helped her and her physician choose the best course of treatment when she was initially given an ambiguous Intermediate result from the 21 gene assay Share This Video http www youtube com watch v Hnj5U7YLnDg Julieta Julieta was originally told she needed chemotherapy but wanted to avoid it Share This Video http www youtube com watch v lIphuIATE94 Julieta Julieta was originally told she needed chemotherapy but wanted to avoid it Share This Video http www youtube com watch v lIphuIATE94 Mary Mary is confident knowing that she really needed chemotherapy Share This Video http www youtube com watch v 5pR423z3sQ4 Mary Mary is confident knowing that she really needed chemotherapy Share This Video http www youtube com watch v 5pR423z3sQ4 Nicole Nicole talks about how MammaPrint may have saved her life by letting her doctors know that her tumor was high risk even though it appeared to be low risk by traditional parameters Share This Video http www youtube com watch v pJ5veMbKKTg Nicole Nicole talks about how MammaPrint may have saved her life by letting her doctors know that her tumor was high risk even though it appeared to be low risk by traditional parameters Share This Video http www youtube com watch v pJ5veMbKKTg Sherri Sherri found it reassuring when her MammaPrint test came back and showed that she had a low risk of recurrence Share This Video

    Original URL path: http://www.agendia.com/patients/ (2016-05-01)
    Open archived version from archive

  • Breast Cancer | Agendia
    can help connect them with a local Agendia Oncology Specialist Cleared by the FDA With FDA clearance have confidence in your results 8 MammaPrint received FDA clearance in 2007 and was the first in vitro diagnostic multivariate index assay IVDMIA to be cleared by the regulatory agency An IVDMIA is a device that combines the values of multiple variables using an interpretative function bioinformatics algorithm to provide a single patient specific result that is intended for use in the diagnosis of disease and which provides a result whose derivation is non transparent and for that reason cannot be independently derived or verified by the end user MammaPrint s FDA clearance confers confidence in its safety and effectiveness ensuring that the peer reviewed published studies used in its development validation and IVDMIA clearance have been evaluated by the United States Food and Drug Administration The FDA label indicates that as a diagnostic tool MammaPrint has a 98 9 degree of accuracy in classifying patients as Low Risk or High Risk and technical reproducibility of 98 5 MammaPrint s FDA indication patient eligibility in the USA Breast cancer recurrence and or metastasis is partly dependent on the activation and suppression of certain genes located within the primary breast tumor The FDA approved MammaPrint profile is a fresh FFPE tissue based genomics test which uses the latest microarray technology to analyze a patient s breast tumor biology to predict whether existing cancer has the ability to metastasize This 70 gene profile is validated as an independent indicator for breast cancer prognosis for women with lymph node negative estrogen receptor positive breast cancer and estrogen receptor negative disease Ask your doctor if the MammaPrint test is right for you Interpreting Your Test Results Agendia provides a summary page designed for patients to help understand their individual results and have a meaningful discussion with their doctor about treatment options The first section is the MammaPrint result which provides you a definitive Low Risk or High Risk risk of recurrence result eliminating the ambiguous intermediate result you can get with other tests The second section is the BluePrint molecular subtyping result This looks deeper than traditional methods and provides more information on which gene pathways are really driving a tumor s growth The third section is the TargetPrint result which provides you an un biased quantitative assessment of ER PR and HER2 expression These results combined with all other factors help you and your doctor make the most appropriate personalized treatment decisions Participate in a clinical registry Current Clinical Registry Trials Agendia s extensive clinical studies and research collaborations have produced numerous retrospective and prospective validation publications over the past decade Recently published studies further support the prognostic and predictive clinical utility of MammaPrint for early stage breast cancer patients and large multi institutional clinical trials such as MINDACT and ISPY 2 can be expected to expand the assay s clinical importance and indications for use Agendia recently published the results from the first ever prospective

    Original URL path: http://www.agendia.com/patient/breast/ (2016-05-01)
    Open archived version from archive

  • Colon Cancer | Agendia
    you definitive results and classifies patients into two distinct groups a Low Risk group low risk of cancer returning and a High Risk group increased risk of cancer returning Most patients with stage II colon cancer are cured by surgery alone These patients are considered Low Risk because they have a very low risk of cancer recurrence also called relapse even without adjuvant chemotherapy However approximately 20 30 of patients are considered High Risk and the probability of disease recurrence or relapse is higher These patients may be candidates for more aggressive treatment regimens to help fight the cancer from returning Traditional clinical factors can help to identify some patients higher risk but unfortunately the risk of most patients is indeterminate This knowledge of your personal risk of recurrence combined with clinical and pathologic characteristics of your tumor help provide you and your physician more information to make the better treatment decisions What does this test mean for me The test report is a genomic fingerprint of your tumor that helps you and your doctor better understand how likely it is that your cancer will recur The result may impact your treatment planning meaning if your result is High Risk your doctor may recommend chemotherapy following surgery and if your result is Low Risk you could be spared unnecessary treatment It is important to understand that having a Low Risk test result does not mean that there is 0 chance that your colon cancer will return and having a High Risk result does not mean that your colon cancer will return These results are meant to aid you and your physician in making the most informed treatment decisions Is ColoPrint right for me ColoPrint is appropriate for patients with newly diagnosed stage II colon cancer Ask your physician if ColoPrint is right for you What is Genomic Testing Genomic tests look at your specific tumor s genes to help find out what s driving its growth Using gene expression testing to help design a tailored treatment plan is called personalized medicine These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer Your physician will assess many factors prior to determining your treatment plan including the size of the tumor lymph node involvement and the hormone receptor status of your cancer These factors along with your tumor s genomic profile can help you and your physician make the most informed treatment decisions for your specific type of cancer ColoPrint Results ColoPrint identifies a patient s risk of distant local or regional relapse and stratifies approximately 2 3 of patients as Low Risk and 1 3 of patients as High Risk A Low Risk result does not guarantee that your tumor will not recur and a High Risk result does not guarantee that it will These results in addition to all other factors help you and your doctor make the most appropriate treatment decisions Low Risk Results A Low Risk result means that a

    Original URL path: http://www.agendia.com/patient/colon-cancer-patients/ (2016-05-01)
    Open archived version from archive

  • Breast Cancer Test Suite | Agendia
    products which help support physicians with their complex treatment decisions Agendia s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome Agendia s tests can help physicians assess a patient s individual risk for metastasis which patients may benefit from chemo hormonal or combination therapy and which patients may not require these treatments and can instead be treated with other less arduous and less costly methods The current breast cancer treatment paradigm is expensive and has significant shortcomings as a result of relatively poor assessment of recurrence risk and over use of chemotherapy Our MammaPrint test has shown a clinically validated ability to predict the risk of breast cancer recurrence in the first five years after diagnosis which is the period in which chemotherapy produces most of its benefits to a patient MammaPrint is the only breast cancer recurrence assay backed by peer reviewed prospective outcome data In addition Agendia has a pipeline of other genomic products in development The company collaborates with pharmaceutical companies leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY 2 and the MINDACT

    Original URL path: http://www.agendia.com/about/ (2016-05-01)
    Open archived version from archive

  • Company Overview | Agendia
    committed to improving the quality of life for cancer patients through molecular diagnostics one patient at a time A growing business We were founded in 2003 as a spin off from the Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital in Amsterdam for the purpose of commercializing molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development In 2004 we launched our first test the MammaPrint 70 gene breast cancer recurrence assay in Europe In 2007 MammaPrint became the first IVDMIA to obtain 510 k clearance from the FDA and after receipt of the regulatory clearance was made commercially available in the United States in 2008 Since the initial 510 k clearance MammaPrint has received four additional FDA clearances Our sixth and most recent 510 k clearance for MammaPrint FFPE was received in February 2015 In 2009 a significant landmark in our commercial development was our positive local coverage determination by the Medicare carrier in California which processes all of our Medicare reimbursement claims MammaPrint is the fastest growing breast cancer recurrence assay and has helped over 48 000 patients from almost 50 countries We d Love To Hear From You Name Email Questions Comments Concerns Questions Comments Concerns

    Original URL path: http://www.agendia.com/about/company-overview/ (2016-05-01)
    Open archived version from archive

  • Leadership | Agendia
    founder Prof Dr René Bernards PhD Chief Scientific Officer CSO and Co founder Guido Brink Vice President of Regulatory Affairs and EU Market Access Bastiaan van der Baan Vice President of Clinical Affairs Business Development Annuska Glas Ph D Vice President Research Product Development Product Support Tammy Marcotte Vice President of Sales US Market Dr Franklin Libenson MD Vice President of Global Marketing and LATAM Market Access Annette Meijering Vice

    Original URL path: http://www.agendia.com/about/executive-management/ (2016-05-01)
    Open archived version from archive